StocksRunner logo
mail
search
 
menu
 
Gilead Sciences
$116.20
+2.65%
 
  Create Alerts  
  
  Overview  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 
 
 
 

GILD

 

Gilead Sciences

$116.20

 
+$3.00 | +2.65%
 
  Create Alerts  
  
  Overview  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 
 
52W High
$ 119.95
 
 
MKT CAP
$ 144.54B
 
52W Low
$ 72.43
 
 
VOL
$ 7.53M
 
P/E Ratio
24.58
 
 
AVG VOL
$ 7.16M
 
RSI
63.03
 
 
TREND
Uptrend
 
 
 

Chart

 
 

$108.91   (+6.69%)

$104.53   (+11.16%)

$116.04   (+0.14%)

$77.73   (+49.49%)

 
 
1year
6month
3month
1month
 
GILD Latest Analysis +
 
 
 
StocksRunner

Explore our GILD Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored GILD Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our GILD Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Plans & Pricing

Contact Us

Terms of use

Privacy Policy

 
 
StocksRunner
 
 
StocksRunner Overview
 
StocksRunner Trending
 
StocksRunner Screener
 
StocksRunner Insights
 
StocksRunner Top Rated
 
StocksRunner Momentum
 
StocksRunner Earnings
mail
 
 

GILD

 

Gilead Sciences

 
 

Current Price

 

$116.20

 
+$3.00 | +2.65%
 
GILD Rating Score

Strong Buy

 
52W High
$ 119.95
 
 
MKT CAP
$ 144.54B
 
52W Low
$ 72.43
 
 
VOL
$ 7.53M
 
P/E Ratio
24.58
 
 
AVG VOL
$ 7.16M
 
RSI
63.03
 
 
TREND
Uptrend
 
 
 
  Create Alerts  
  
  Overview  
  
  Insights  
  
   Risks   
  
  Rating  
  
  Chart  
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
 
 
 
 
 
 

GILD Stock Rating

 
lock  Login to view Gilead Sciences (GILD) recommendation from the last 90 days from financial news and social media.
 

Chart

 
 

$108.91   (+6.69%)

$104.53   (+11.16%)

$116.04   (+0.14%)

$77.73   (+49.49%)

 
 
1year
6month
3month
1month
 
 
 
 
 

GILD Latest Analysis

 
 
 

Nasdaq 100 Movers: CHTR GILD. In early trading on Friday shares of Gilead Sciences topped the list of the days best performing components of the Nasdaq 100 index trading up 2.9%. Year to date Gilead Sciences registers a 26.1% gain.And the worst performing Nasdaq 100 component thus far on the day is C

 

Today

$116.20 | +2.65%
 
Momentum
Momentum

Gileads Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales. In June the United States Food and Drug Administration (FDA) approved) Yeztugo(lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg making it the first and only twice-yearly option available in the United States for people.Data show that ≥99.9% of participants who received Yeztugo in the Phase 3 PURPOSE 1 and PURPOSE 2 trials r

 

Today

$116.20 | +2.65%
 
Activity
Potential

Gilead upgraded to Buy at Needham on new HIV drug.

 

Today

$116.20 | +2.65%
 
Rating

This Gilead Sciences Analyst Turns ish. Here Are Top 5 Upgrades For Friday. Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes including upgrades downgrades and initiations please see our analyst ratings page.Needham analyst Joseph Stringer upgraded the rating for ) from Hold to Buy and announced a $133 price target. Gilead Sciences shares closed at $113.20 on Thursday. See how other analysts view this stock.Mizuho analyst Dan Dol

 

Today

$116.20 | +2.65%
 
Potential
Rating

Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention. MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527 aiming to rival Gileads daily PrEP options.

 

Tue Jul 15, 2025

$109.06 | -2.70%
 
Activity

Gilead Sciences (GILD) Reaches Deal to Offer HIV Vaccine to Low and Middle-Income Nations.

 

Tue Jul 15, 2025

$109.06 | -2.70%
 
Activity

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today. Gilead Sciences (NASDAQ:) has outperformed the market over the past 15 years by 1.24% on an annualized basis producing an average annual return of 13.62%. Currently Gilead Sciences has a market capitalization of $139.43 billion.

 

Mon Jul 14, 2025

$112.09 | +2.23%
 
Activity

Gilead twice-yearly HIV prevention drug Yeztugo recommended by WHO.

 

Mon Jul 14, 2025

$112.09 | +2.23%
 
Potential

Gileads Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million. ) on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS Tuberculosis and Malaria to supply lenacapavir — Gilead’.s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as .Through the agreement Gilead will supply enough doses to reach up to two million people over three years in countries supported by the Global Fund at no profit to Gilea

 

Wed Jul 9, 2025

$113.24 | +1.96%
 
Activity

Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet. Based on the average brokerage recommendation (ABR) Gilead (GILD) should be added to ones portfolio. Wall Street analysts overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So is the stock worth buying?

 

Wed Jul 9, 2025

$113.24 | +1.96%
 
Potential

 
 
 
 
 
StocksRunner

Discover GILD Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of GILD. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our GILD Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

GILD Stock trends

GILD Stock performance

GILD Stock analysis

GILD investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo
 

UnAlert GILD Runner Alarm

Real-time signals powered by data
×

Price-Based

Triggers when the stock breaks through a known resistance level
 
Triggers when the stock drops below a key support level
 
Notifies if the stock moves up/down by a set percentage (e.g. ±5%)
 
Alerts when the stock hits a new high or low
 
Signals proximity to long-term highs or lows (e.g. within 5%)
 

Technical Indicator (Pro Plan)

Volume spikes 2x–3x above average. Indicates strong buying/selling pressure
 
Tracks large intraday swings, signaling potential opportunities or risk
 
Signals potential trend reversals or continuations
 
Long-term bullish/bearish trend signals from MA crossovers
 
RSI above 70 or below 30 to identify possible reversals
 
Signals momentum shifts
 

Fundamental (Master Plan)

Upcoming or just-released earnings reports
 
Alerts after results compared to expectations
 
Changes in rating or target price
 
New or changed dividends
 
Large trades by company insiders
 
M&A, lawsuits, product launches, etc
 
High volume/open interest in call/put contracts
 
Surge in mentions or sentiment shifts
 

 
 
Post ×
 
0/666
joker
 
 
 
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Credibility Score

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing GILD

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

 
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Credibility Score

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing GILD

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.